Verve Therapeutics Inc (VERV)
4.595
+0.04
(+0.99%)
USD |
NASDAQ |
Nov 21, 16:00
4.595
0.00 (0.00%)
After-Hours: 20:00
Verve Therapeutics Enterprise Value: -154.70M for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | -154.70M |
| November 19, 2024 | -130.15M |
| November 18, 2024 | -158.93M |
| November 15, 2024 | -134.38M |
| November 14, 2024 | -84.43M |
| November 13, 2024 | -49.72M |
| November 12, 2024 | 2.775M |
| November 11, 2024 | 3.622M |
| November 08, 2024 | -5.691M |
| November 07, 2024 | -1.458M |
| November 06, 2024 | 2.775M |
| November 05, 2024 | 0.235M |
| November 04, 2024 | -27.70M |
| November 01, 2024 | -37.86M |
| October 31, 2024 | -54.80M |
| October 30, 2024 | -49.72M |
| October 29, 2024 | -32.78M |
| October 28, 2024 | -37.17M |
| October 25, 2024 | -34.63M |
| October 24, 2024 | -55.79M |
| October 23, 2024 | -71.02M |
| October 22, 2024 | -58.33M |
| October 21, 2024 | -70.17M |
| October 18, 2024 | -61.71M |
| October 17, 2024 | -77.79M |
| Date | Value |
|---|---|
| October 16, 2024 | -65.94M |
| October 15, 2024 | -66.79M |
| October 14, 2024 | -114.19M |
| October 11, 2024 | -144.66M |
| October 10, 2024 | -150.58M |
| October 09, 2024 | -153.12M |
| October 08, 2024 | -157.35M |
| October 07, 2024 | -134.50M |
| October 04, 2024 | -116.73M |
| October 03, 2024 | -140.42M |
| October 02, 2024 | -133.65M |
| October 01, 2024 | -134.50M |
| September 30, 2024 | -130.27M |
| September 27, 2024 | -154.52M |
| September 26, 2024 | -156.21M |
| September 25, 2024 | -172.29M |
| September 24, 2024 | -157.06M |
| September 23, 2024 | -151.13M |
| September 20, 2024 | -136.75M |
| September 19, 2024 | -120.67M |
| September 18, 2024 | -109.67M |
| September 17, 2024 | -119.82M |
| September 16, 2024 | -117.28M |
| September 13, 2024 | -110.51M |
| September 12, 2024 | -97.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-206.69M
Minimum
Jun 27 2024
3.133B
Maximum
Sep 10 2021
785.66M
Average
602.11M
Median
Dec 18 2023
Enterprise Value Benchmarks
| Ardelyx Inc | 1.076B |
| Biomarin Pharmaceutical Inc | 11.59B |
| Sage Therapeutics Inc | -268.79M |
| ALX Oncology Holdings Inc | -74.92M |
| Immuneering Corp | 12.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.13M |
| Revenue (Quarterly) | 6.865M |
| Total Expenses (Quarterly) | 63.78M |
| EPS Diluted (Quarterly) | -0.59 |
| Profit Margin (Quarterly) | -730.3% |
| Earnings Yield | -53.54% |
| Normalized Earnings Yield | -53.54 |